ANAVEX LIFE SCIENCES CORP. — Director's Dealing 2025

Jan 18, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK: 0001314052
Period of Report: 2025-01-15

Reporting Person: MISSLING CHRISTOPHER U (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-15	Stock Option (Right to Buy)	$7.54	A	166666	Acquired	2032-06-14	Common Stock (166000)	Direct
2025-01-15	Stock Option (Right to Buy)	$8.57	A	125000	Acquired	2032-06-14	Common Stock (125000)	Direct

Footnotes

F1: On June 14, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in three equal tranches based on performance milestones, one of which was completion of Phase 2b/3 study for Alzheimer's disease. The performance criteria for this milestone was met with the final publication of all clinical trial data, resulting in vesting of the option as to 166,000 shares.

F2: On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of AD-004 Alzheimer's disease study. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.